Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Receivables (2016 - 2025)

Ocular Therapeutix has reported Receivables over the past 13 years, most recently at $30.6 million for Q4 2025.

  • Quarterly results put Receivables at $30.6 million for Q4 2025, down 5.37% from a year ago — trailing twelve months through Dec 2025 was $30.6 million (down 5.37% YoY), and the annual figure for FY2025 was $30.6 million, down 5.37%.
  • Receivables for Q4 2025 was $30.6 million at Ocular Therapeutix, roughly flat from $30.8 million in the prior quarter.
  • Over the last five years, Receivables for OCUL hit a ceiling of $32.4 million in Q4 2024 and a floor of $13.6 million in Q1 2021.
  • Median Receivables over the past 5 years was $24.4 million (2023), compared with a mean of $24.6 million.
  • Biggest five-year swings in Receivables: skyrocketed 551.84% in 2021 and later dropped 8.98% in 2023.
  • Ocular Therapeutix's Receivables stood at $21.1 million in 2021, then increased by 0.9% to $21.3 million in 2022, then increased by 22.76% to $26.2 million in 2023, then increased by 23.72% to $32.4 million in 2024, then dropped by 5.37% to $30.6 million in 2025.
  • The last three reported values for Receivables were $30.6 million (Q4 2025), $30.8 million (Q3 2025), and $30.4 million (Q2 2025) per Business Quant data.